Thomas Johnson, MD
Allergy & Immunology · Gainesville, FLNPI 1255399226
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $325,295 of the $361,104 with a category attached, or 90.1%. 30 manufacturers reported payments, led by GSK at 43.5% of the total. Reporting peaked in 2023 at $137,636 and has fallen 91.1% since, to $12,261 in 2025. Among allergy & immunology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 826 payments — averaging $437.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$157K
- AstraZeneca$145K
- Optinose US, Inc.$48K
- Amgen$3K
- Sanofi$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $5K from 24 others
Across 39 payments — averaging $2976.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$95K
- Astrazeneca UK Limited$21K
What the payments were for
- Consulting fees$3,6251%
- Speaking & faculty fees$325,29590%
- Travel & lodging$12,0233%
- Food & beverage$20,0136%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 194 | $157,127 |
| AstraZeneca | 197 | $145,229 |
| Optinose US, Inc. | 119 | $48,387 |
| Amgen | 5 | $2,959 |
| Sanofi | 48 | $1,336 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $1,170 |
| Regeneron Healthcare Solutions, Inc. | 40 | $883 |
| Novartis | 23 | $565 |
| Covis Pharma GmbH | 24 | $519 |
| Biocryst US Sales Co., LLC | 17 | $412 |
| Grifols USA, LLC | 20 | $380 |
| CSL Behring | 11 | $255 |
| Genentech USA, Inc. | 14 | $242 |
| Pfizer | 9 | $194 |
| AbbVie | 5 | $192 |
| Kaleo, Inc. | 11 | $182 |
| Pharming Healthcare, Inc. | 10 | $180 |
| Octapharma USA, Inc. | 7 | $168 |
| Aimmune Therapeutics, Inc. | 6 | $126 |
| Boehringer Ingelheim | 4 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Alk-abello, Inc | 2 | $66 |
| Mylan Specialty L.p. | 3 | $59 |
| LEO Pharma Inc. | 3 | $54 |
| Blueprint Medicines Corporation | 2 | $53 |
| Greer Laboratories, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Eyevance Pharmaceuticals LLC | 1 | $22 |
| Merck | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$361,104 in reported general payments places this provider in the 95th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 59 | $230,221 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 34 | $154,768 |
| XolairOmalizumab | 31 | $128,791 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $76,909 |
| Spiriva RespimatTiotropium Bromide | 34 | $31,729 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $31,126 |
| Arnuity ElliptaFluticasone Furoate | 52 | $16,294 |
| AirsupraAlbuterol Sulfate/Budesonide | 18 | $10,967 |
| Epinephrine | 57 | $10,211 |
| XhanceFluticasone Propionate | 14 | $8,689 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $8,501 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $4,623 |
| Advair DiskusFluticasone Propion/Salmeterol | 13 | $3,745 |
| Ipratropium Bromide | 111 | $3,627 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $3,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $255 | $154,76834 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $157,127 | $124,329186 claims |
| Boehringer IngelheimSpiriva Respimat | $114 | $31,72934 claims |
| AstraZenecaAirsupra, Symbicort, Pulmicort Flexhaler | $145,229 | $22,42452 claims |
| Optinose US, Inc.Xhance | $48,387 | $8,68914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Gainesville
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
- Sofia SzariEglin Afb$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.